Revenue growth of 10-12% across segments
Management expects 10-12% growth in domestic, branded exports, and generic businesses; API slightly lower.
IPCALABORATORIES / guidance tracker
Keep management guidance in view.
IPCA Laboratories · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
growth
Annual EBITDA margin expansion of ~150 bps
At 10-11% topline growth, EBITDA margin should improve by ~1.5% per year.
Unichem to achieve 15% EBITDA margin in 2-3 years
Unichem aims for 15% EBITDA margin in 2-3 years, then gradually to 20% as European filings commercialize.
5-7 new US product launches from IPA portfolio in 12-15 months
IPA will commercialize 5-7 additional molecules in the US over next 12-15 months, adding to existing 5.